Matthew L. Kaplan - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Matthew L. Kaplan has filed 1 SEC Form 4 filing across 1 company in the last 90 days - buying. Lifetime open-market purchases: $64K.
Profile
Matthew L. Kaplan holds the role of Director at Nuvectis Pharma, Inc. (NVCT). Kaplan has reported 2 insider filings with the SEC since 2025. The most recent filing was in June 2026.
| Role | Director |
|---|---|
| Notability | 26/100 |
Board memberships
- Nuvectis Pharma, Inc.
Reported roles
- Director
Trading Pattern
InsiderAlpha's records for Matthew L. Kaplan go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. The typical open-market purchase is $64K (1 buy totaling $64K). The largest single buy on record is $64K of NVCT in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Matthew L. Kaplan has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at Nuvectis Pharma, Inc. (NVCT) - 2 filings, 2025 to 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | NVCT | Nuvectis Pharma, Inc. | A - Grant or award | 35.0K | $0.00 | |
| 2025-11-06 | NVCT | Nuvectis Pharma, Inc. | P - Open-market purchase | 11.0K | $5.84 | $64K |
Companies - Last 90 Days
- Nuvectis Pharma, Inc. (NVCT) - 1 filing, last 2026-06-12
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Matthew L. Kaplan has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Marlio Charles Mosseri - $1.87M of NVCT open-market activity in the last 12 months
- Ron Bentsur - $279K of NVCT open-market activity in the last 12 months
- Juan Sanchez - $75K of NVCT open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Neil Mehta
- Keith A. Meister
- John Micek
- Andrew J. Mills
- Charles N. Mills
- Mink Brook Asset Management LLC
- Shankh Mitra
- MITSUI SUMITOMO INSURANCE CO LTD
Frequently Asked Questions
Who is Matthew L. Kaplan?
Matthew L. Kaplan holds the role of Director at Nuvectis Pharma, Inc. (NVCT). Kaplan has reported 2 insider filings with the SEC since 2025. The most recent filing was in June 2026.…
How many SEC Form 4 filings has Matthew L. Kaplan submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Matthew L. Kaplan been buying or selling stock?
Recorded transactions: 1 open-market purchase ($64K) and 0 open-market sales across all tracked filings.
Where can I see all of Matthew L. Kaplan's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Matthew L. Kaplan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.